Skip to content

Study · Observational study · n = 3,782 · 2023

6 results

Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.

Hoog M, Paczkowski R, Huang A, Halpern R, Buysman E, Stackland S, Zhang Y, Wangia-Dixon R

Diabetes therapy : research, treatment and education of diabetes and related disorders23 Sept 2023

PMID37740872 (opens in a new tab)PMCIDPMC10570245 (opens in a new tab)DOI10.1007/s13300-023-01473-7 (opens in a new tab)PepBankPUB-37740872
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In elderly patients with type 2 diabetes, dulaglutide initiation was linked to greater HbA1c reduction than basal insulin initiation.

    In plain wordsIn elderly patients with diabetes, dulaglutide was linked to a greater HbA1c reduction than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n = 3,782

    Comparator
    Basal insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.95%
    dulaglutide
    HbA1c change
    −0.69%
    basal insulin

    Source sentences

    Summary
    The dulaglutide cohort had significantly greater mean HbA1c reduction from baseline to follow-up than basal insulin cohort (- 0.95% vs - 0.69%; p < 0.001).
    3 context sentences
    Summary · context
    This observational, retrospective cohort study used data from the Optum Research Database.
    Summary · context
    Medicare Advantage patients (≥ 65 years) with T2D were assigned to dulaglutide or basal insulin cohorts based on pharmacy claims and propensity score matched on demographic and baseline characteristics.
    Summary · context
    Propensity score matching yielded well-balanced cohorts with 1891 patients each (mean age: dulaglutide, 72.09 years; basal insulin, 72.56 years).
  2. 02HumanObservational studyOther

    In elderly patients with diabetes, dulaglutide was linked to lower all-cause medical costs than basal insulin ($8306 versus $12,176).

    In plain wordsIn elderly patients with diabetes, dulaglutide was linked to lower medical costs than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAll-cause medical costs
    Study

    n = 3,782

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    All-cause medical costs
    8306 USD
    dulaglutide
    All-cause medical costs
    12,176 USD
    basal insulin

    Source sentences

    Summary
    The dulaglutide cohort had significantly lower mean all-cause and diabetes-related medical costs (all-cause: $8306 vs $12,176; diabetes-related: $4681 vs $7582 respectively; p < 0.001) and lower mean all-cause total costs ($18,646 vs $20,972, respectively; p = 0.007) than basal insulin cohort.
    3 context sentences
    Summary · context
    This observational, retrospective cohort study used data from the Optum Research Database.
    Summary · context
    Medicare Advantage patients (≥ 65 years) with T2D were assigned to dulaglutide or basal insulin cohorts based on pharmacy claims and propensity score matched on demographic and baseline characteristics.
    Summary · context
    Propensity score matching yielded well-balanced cohorts with 1891 patients each (mean age: dulaglutide, 72.09 years; basal insulin, 72.56 years).
  3. 03HumanObservational studyOther

    In elderly patients with diabetes, dulaglutide was linked to lower diabetes-related medical costs than basal insulin.

    In plain wordsIn elderly patients with diabetes, dulaglutide was linked to lower diabetes medical costs than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseDiabetes-related medical costs
    Study

    n = 3,782

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Diabetes medical costs
    4681 USD
    dulaglutide
    Diabetes medical costs
    7582 USD
    basal insulin

    Source sentences

    Summary
    The dulaglutide cohort had significantly lower mean all-cause and diabetes-related medical costs (all-cause: $8306 vs $12,176; diabetes-related: $4681 vs $7582 respectively; p < 0.001) and lower mean all-cause total costs ($18,646 vs $20,972, respectively; p = 0.007) than basal insulin cohort.
    3 context sentences
    Summary · context
    This observational, retrospective cohort study used data from the Optum Research Database.
    Summary · context
    Medicare Advantage patients (≥ 65 years) with T2D were assigned to dulaglutide or basal insulin cohorts based on pharmacy claims and propensity score matched on demographic and baseline characteristics.
    Summary · context
    Propensity score matching yielded well-balanced cohorts with 1891 patients each (mean age: dulaglutide, 72.09 years; basal insulin, 72.56 years).
  4. 04HumanObservational studyOther

    In elderly patients with diabetes, dulaglutide was linked to lower all-cause total costs than basal insulin ($18,646 versus $20,972).

    In plain wordsIn elderly patients with diabetes, dulaglutide was linked to lower total costs than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAll-cause total costs
    Study

    n = 3,782

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    All-cause total costs
    18,646 USD
    dulaglutide
    All-cause total costs
    20,972 USD
    basal insulin

    Source sentences

    Summary
    The dulaglutide cohort had significantly lower mean all-cause and diabetes-related medical costs (all-cause: $8306 vs $12,176; diabetes-related: $4681 vs $7582 respectively; p < 0.001) and lower mean all-cause total costs ($18,646 vs $20,972, respectively; p = 0.007) than basal insulin cohort.
    3 context sentences
    Summary · context
    This observational, retrospective cohort study used data from the Optum Research Database.
    Summary · context
    Medicare Advantage patients (≥ 65 years) with T2D were assigned to dulaglutide or basal insulin cohorts based on pharmacy claims and propensity score matched on demographic and baseline characteristics.
    Summary · context
    Propensity score matching yielded well-balanced cohorts with 1891 patients each (mean age: dulaglutide, 72.09 years; basal insulin, 72.56 years).
  5. 05HumanObservational studyOther

    In elderly patients with diabetes, all-cause costs per 1% HbA1c change were lower with dulaglutide than basal insulin ($19,729 versus $30,334).

    In plain wordsIn elderly patients with diabetes, dulaglutide was linked to lower costs per HbA1c improvement than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAll-cause costs per HbA1c change
    Study

    n = 3,782

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    All-cause total costs per 1% HbA1c change
    19,729 USD
    dulaglutide
    All-cause total costs per 1% HbA1c change
    30,334 USD
    basal insulin

    Source sentences

    Summary
    The dulaglutide cohort had significantly lower all-cause and diabetes-related total costs per 1% change in HbA1c than basal insulin cohort (all-cause: $19,729 vs $30,334; diabetes-related: $12,842 vs $17,288, respectively; p < 0.001).
    3 context sentences
    Summary · context
    This observational, retrospective cohort study used data from the Optum Research Database.
    Summary · context
    Medicare Advantage patients (≥ 65 years) with T2D were assigned to dulaglutide or basal insulin cohorts based on pharmacy claims and propensity score matched on demographic and baseline characteristics.
    Summary · context
    Propensity score matching yielded well-balanced cohorts with 1891 patients each (mean age: dulaglutide, 72.09 years; basal insulin, 72.56 years).
  6. 06HumanObservational studyOther

    In elderly patients with diabetes, diabetes-related costs per 1% HbA1c change were lower with dulaglutide than basal insulin ($12,842 versus $17,288).

    In plain wordsIn elderly patients with diabetes, dulaglutide was linked to lower diabetes costs per HbA1c improvement than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseDiabetes costs per HbA1c change
    Study

    n = 3,782

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Diabetes-related total costs per 1% HbA1c change
    12,842 USD
    dulaglutide
    Diabetes-related total costs per 1% HbA1c change
    17,288 USD
    basal insulin

    Source sentences

    Summary
    The dulaglutide cohort had significantly lower all-cause and diabetes-related total costs per 1% change in HbA1c than basal insulin cohort (all-cause: $19,729 vs $30,334; diabetes-related: $12,842 vs $17,288, respectively; p < 0.001).
    3 context sentences
    Summary · context
    This observational, retrospective cohort study used data from the Optum Research Database.
    Summary · context
    Medicare Advantage patients (≥ 65 years) with T2D were assigned to dulaglutide or basal insulin cohorts based on pharmacy claims and propensity score matched on demographic and baseline characteristics.
    Summary · context
    Propensity score matching yielded well-balanced cohorts with 1891 patients each (mean age: dulaglutide, 72.09 years; basal insulin, 72.56 years).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.